ABCSG 36/Penelope summary

Phase-III-study evaluating palbociclib, a cyclin-dependent kinase (CDK) 4/6 inhibitor in patients with hormonereceptor-positive, HER2-normal primary breast cancer with high relapse risk after neoadjuvant chemotherapy.

Start: 12/2013, national: 12/2014
Coordinating investigator: Gnant, Michael; Wien
Sample size: 1.100